Skip to content

Ketamine: all studies

Page 355 of 449: studies 3,541 to 3,550 of 4,483, newest first. Back to the ketamine overview

Research

Temporal structure of psychedelic EEG: statistical unit, dose, and receptor mechanism in multi-scale dynamics

Zenodo (CERN European Organization for Nuclear Research) September 7, 2026 Flávio Marco Rego da Silva preprint

Rationale: Increased neural complexity under psychedelics is replicated, but the temporal structure carrying it — and the design choices that decide what a "complexity increase" means — remain contested: window-level reports treat correlated windows as independent; cross-dataset contrasts confound pharmacology with protocol. Objectives: To test, in public EEG datasets with pre-registered...

Through the Looking-Glass: A Scoping Review of Psychological Mechanisms of Psychedelic-Assisted Therapy for Substance Use Disorders

Current Addiction Reports September 2, 2026 Kathryn Fletcher, Jack Freestone, Nadine Ezard et al.

Abstract Purpose of Review Psychedelic-assisted therapy (PAT) has re-emerged as a potential intervention for substance use disorders (SUDs), yet the psychological mechanisms underlying behaviour change remain poorly synthesised. This scoping review mapped and evaluated proposed psychological processes underpinning PAT in adults with SUDs. Recent Findings Peer-reviewed English-language empirical...

Psychopharmacology at an Inflection Point: From Syndromes to Stratified Mechanisms, Circuit-Based Treatments, and Precision Psychiatry.

Journal of Psychiatric Practice September 1, 2026 Matthew Macaluso

Psychopharmacology, once propelled by a series of serendipitous mid-20th-century discoveries, has matured into a field defined by mechanistic diversity, translational neuroscience, and an expanding array of circuit-based interventions. Despite more than 100 approved psychiatric drugs, remission rates for major depressive disorder and other serious mental disorders remain modest, underscoring...

DOI: 10.1097/pra.0000000000000947 (opens in new tab) Full text (opens in new tab) Artificial intelligence Drug development Glutamatergic neurotransmission Muscarinic receptor agonists +5

A national approach in a European context: Multidisciplinary and multiprofessional recommendations on the clinical use of psychedelic substances

Neuroscience Applied September 1, 2026 Carolina Seybert, Ana Matos Pires, Luís Madeira et al.

The therapeutic benefits of psychedelics for neuropsychiatric conditions have gathered significant attention in Europe and around the world, with treatments using psilocybin, MDMA, and ketamine as notable examples. However, the mind-altering effects of these substances, and the complexity of their regulatory frameworks, both within and outside of therapeutic use, imply careful clinical...

The mPFC-reuniens-hippocampus pathway links brain circuitry and neural plasticity in antidepressant response

Nature Communications September 1, 2026 Maxime Veleanu, Louise E. Schuberth, Antje Kilias et al.

The pathophysiology of depression involves multiple biological processes, including circuit dysfunction and impaired neuroplasticity, yet an integrative view linking these processes remains elusive. Here, we identify a convergent circuit for antidepressant response and plasticity modulation. We demonstrate that chemogenetic activation of the infralimbic cortex (IL) exerts rapid...

Patterns of Psychedelic Use in Italy: Insights from the Global Psychedelic Survey

Clinical Neuropsychopharmacology and Addiction September 1, 2026 Beatrice Dal Bianco, Matteo Buonarroti, Alessandro Lo Jacono et al.

Background: Epidemiological data on psychedelic use in Italy is limited. In this study, Italian responders in the Global Psychedelic Survey 2025 were subanalyzed to describe patterns of use, motivations, subjective experiences, and health correlates. Methods: Adults (≥21 years) with lifetime psychedelic exposure, residing in or born in Italy or San Marino, were surveyed in a web-based,...

Beyond the Edge of Chaos: A Bidirectional Critical Reconstructability Corridor Hypothesis for Consciousness-Relevant Neural Dynamics

Zenodo (CERN European Organization for Nuclear Research) August 30, 2026 Pasquale Kaboth preprint

This work introduces the Critical Reconstructability Corridor (CRC) hypothesis, a theoretical, computational, and empirically testable framework for investigating consciousness-relevant neural dynamics beyond the conventional notion of a single “edge of chaos.” The central proposal is that biological dynamics capable of supporting consciousness may occupy a bounded, multidimensional and...

Uso da cetamina no tratamento da depressão maior resistente ao tratamento

Brazilian Journal of Implantology and Health Sciences August 26, 2026 Kristen Garcia Costa, Gabriela Sensi Santhiago, Daniel Cardoso Madeira et al.

Introdução: O transtorno depressivo maior constitui uma importante causa de incapacidade e comprometimento da qualidade de vida. Entre os pacientes que não apresentam resposta adequada a tratamentos antidepressivos convencionais, destaca-se a depressão resistente ao tratamento, para a qual permanecem limitações terapêuticas relevantes. Nesse contexto, a cetamina e a esketamina surgiram como...

Investigation of Potential Therapeutic Effects of New Rapid-Acting Antidepressant Drugs (RAADs) Using Stress-Based Models of Depression

Biomolecules August 24, 2026 Agnieszka Pałucha-Poniewiera

The use of animal models to study mental illnesses, such as depression, requires proper standardization and extensive expertise. Achieving good construct, face, and predictive validity in depression models is quite challenging. Currently, only a few environmental models, mostly based on chronic stress, and a limited number of genetic models fulfill these criteria. In the quest for new...

Treatment-resistant depression: Current therapeutic strategies

International Health Sciences Review August 18, 2026 Samuel Cândido Freres, Marco Antonio Franco Cançado, Aline Ferreira Catrolio et al.

Treatment-resistant depression (TRD) represents one of the most complex forms of major depressive disorder, characterized by the persistence of clinically significant symptoms despite the performance of appropriate therapeutic interventions. This condition is associated with a worse prognosis, higher risk of recurrence, functional impairment, increased morbidity and mortality, and high...